FAS and metabolic dysfunction-associated steatotic liver disease: The results of the present study reveal that DOFP decreased FAS, FATP2 and SCD-1 expression in the liver of NAFLD mice, which was consistent with the increased MUFA content in model mice and the decrease of SFA and stearic acid with the DOFP use.